Digest Network Come funziona
Network
/
Società
Ky
Non verificato

Kyowa Kirin

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina Salute BenessereSalute

18 comunicati stampa

Guarda tutti i comunicati
21/07/2026
Industria
Salute
Biotecnologia
Sanità
Farmaceutica
European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
Fonte
Kyowa Kirin
Emittente
Business Wire
1.00
0
30/06/2026
Farmaceutica
Medicina Salute Benessere
New Analyses Advance Understanding of Long-Term Survival Outcomes with Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
29/06/2026
Farmaceutica
Medicina Salute Benessere
New PROSPER Data Demonstrate Real-World Impact of Mogamulizumab on Symptoms and Health-Related Quality of Life in Mycosis Fungoides and Sézary Syndrome
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmaceutica
Medicina Salute Benessere
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
24/04/2026
Biotecnologia
Annunci Economici
Medicina Salute Benessere
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
03/03/2026
Annunci Economici
Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
31/01/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
31/01/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Kyowa Kirin recupera el control del programa de desarrollo y comercialización de rocatinlimab, demostrando un firme compromiso para abordar la elevada necesidad médica no cubierta en la dermatitis atópica
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
30/01/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Fonte
Kyowa Kirin
Emittente
GLOBENEWSWIRE
1.00
0
11/12/2025
Mercato del lavoro
Industria
Finanza
Biotecnologia
Medicina - Varie
Associazioni/Professionisti
Sanità
Salute
Farmaceutica
Oncologia
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman
Fonte
Kyowa Kirin
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0